Skip to content
Evigrade
CriticalClass Ic antiarrhythmic×Atypical antipsychotic – indole derivative

Updated · Methodology

Mechanism

Ziprasidone causes mild to moderate, dose-dependent QT prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Flecainide, a class IC antiarrhythmic, slows conduction in the heart. Its Spanish SmPC states that it prolongs the QT interval and widens the QRS complex by 12–20%. According to the US label, QT lengthening is dose-related and averages about 8%, mostly because the QRS widens. Rare cases of torsade de pointes have been reported with flecainide (flecainide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). No studies have looked at ziprasidone together with other QT-prolonging drugs, and an additive effect cannot be excluded (ziprasidone SmPC, AEMPS). CYP2D6 plays a large part in flecainide metabolism, and drugs that inhibit it can raise flecainide levels. Both the Spanish SmPC and the US label of ziprasidone say it is unlikely to change the metabolism of CYP2D6 substrates to a clinically relevant degree (flecainide and ziprasidone SmPCs, AEMPS; ziprasidone label, FDA).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Like other antiarrhythmics, flecainide can cause new or worse arrhythmias, including more frequent extrasystoles and more severe ventricular tachycardia. It can also cause atrioventricular block, a slow heart rate and sinus arrest (flecainide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). In people taking QT-prolonging drugs, a slow heart rate, low potassium or magnesium, and the use of other such drugs raise the risk of torsade de pointes and sudden death (ziprasidone label, FDA). Low or high potassium can also alter the effect of flecainide (flecainide label, FDA).

Management

The combination is contraindicated under the Spanish ziprasidone summaries of product characteristics (SmPCs), for both the originator and the generic. They contraindicate ziprasidone with QT-prolonging drugs and give such drugs as examples, not as a closed list (ziprasidone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Flecainide is not among the examples. However, its own Spanish SmPC states directly that it prolongs the QT interval, and its US label says that QT lengthening is dose-related. The contraindication therefore covers flecainide too (flecainide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The US label says not to combine ziprasidone with drugs that have demonstrated QT prolongation and to avoid it in people with a history of cardiac arrhythmias (ziprasidone label, FDA). Ziprasidone is also contraindicated in known QT prolongation and decompensated heart failure, and flecainide in heart failure (ziprasidone and flecainide SmPCs, AEMPS). Correct low potassium and magnesium before starting ziprasidone, and low or high potassium and other electrolyte disturbances before starting flecainide (ziprasidone and flecainide SmPCs, AEMPS). If palpitations, vertigo, fainting or seizures appear during ziprasidone treatment, carry out a cardiac assessment including an electrocardiogram (ECG). If the heart-rate-corrected QT interval (QTc) exceeds 500 ms, the SmPC recommends interrupting ziprasidone (ziprasidone SmPC, AEMPS). If the PR interval reaches 0.30 seconds or QRS reaches 0.18 seconds, continue flecainide with caution and consider a lower dose. Stop flecainide in second- or third-degree atrioventricular block unless a pacemaker is in place (flecainide label, FDA). No document gives an interval between stopping one drug and starting the other. The half-life of flecainide is about 20 hours (12–27 hours), and the mean half-life of oral ziprasidone is 6.6 hours (flecainide and ziprasidone SmPCs, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Flecainide

Other interactions with Ziprasidone